(19)
(11) EP 4 453 028 A1

(12)

(43) Date of publication:
30.10.2024 Bulletin 2024/44

(21) Application number: 22844046.7

(22) Date of filing: 21.12.2022
(51) International Patent Classification (IPC): 
C07K 16/18(2006.01)
 A61P 27/02(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/18; C07K 2317/76; A61P 27/02; C07K 2317/622; C07K 2317/94; C07K 2317/92; C07K 2317/24; C07K 2317/70
(86) International application number:
PCT/EP2022/087260
(87) International publication number:
WO 2023/118312 (29.06.2023 Gazette 2023/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 22.12.2021 US 202163292513 P

(71) Applicants:
  • CDR-Life AG
    8810 Horgen (CH)
  • Boehringer Ingelheim International GmbH
    55216 Ingelheim am Rhein (DE)

(72) Inventors:
  • BORRAS, Leonardo
    8810 Horgen (CH)
  • GUPTA, Pankaj
    Ridgefield, Connecticut 06877-0368 (US)
  • HOERER, Stefan
    55216 Ingelheim am Rhein (DE)
  • JUNGMICHEL, Stephanie
    8810 Horgen (CH)
  • LEISNER, Christian
    8800 Thalwil (CH)
  • REINDL, Sophia
    55216 Ingelheim am Rhein (DE)
  • RICHLE, Philipp Robert
    8037 Zuerich (CH)
  • SCHEIFELE, Fabian
    8810 Horgen (CH)
  • SOBIERAJ, Anna
    8810 Horgen (CH)

(74) Representative: Lutze, Oliver et al
Boehringer Ingelheim International GmbH Binger Straße 173
55216 Ingelheim am Rhein
55216 Ingelheim am Rhein (DE)

   


(54) ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES